Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Teva Pharmaceutical IndustriesLTS:0LER +2.20%39 EV-to-OCF is 30.50 as of Sep. 17, 2026, which is 5% above its 10-year median of 28.96. GuruFocus rates LTS:0LER with a GF Score™ of 39/100 and a GF Value™ of $20.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks worse than 79.34% on this metric.
The historical rank and industry rank for Teva Pharmaceutical Industries's EV-to-OCF or its related term are showing as below:
LTS:0LER'
s EV-to-OCF Range Over the Past 10 Years
Min: 12.69 Med: 28.96 Max: 80.31
Current: 29.63
During the past 13 years, the highest EV-to-OCF of Teva Pharmaceutical Industries was 80.31. The lowest was 12.69. And the median was 28.96.
LTS:0LER's EV-to-OCF is ranked worse than 79.34% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.15
vs LTS:0LER: 29.63
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Teva Pharmaceutical Industries's PE Ratio (TTM) for today is calculated as:
Teva Pharmaceutical Industries's share price for today is $37.10.
Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.595.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Teva Pharmaceutical Industries EV-to-OCF Related Terms
Teva Pharmaceutical Industries EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's EV-to-OCF falls into.
Teva Pharmaceutical Industries's current Enterprise Value is $57,889 Mil.
Teva Pharmaceutical Industries's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,898 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (LTS:0LER) has a EV-to-OCF of 30.50 as of Sep. 17, 2026. This is near median its historical median of 28.96. Over the past decade, Teva Pharmaceutical Industries' EV-to-OCF has ranged from 12.69 to 80.31. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #799 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is Teva Pharmaceutical Industries' EV-to-OCF too high?
Teva Pharmaceutical Industries' current EV-to-OCF of 30.50 is near median its 10-year median of 28.96. Over the past 10 years, this metric has ranged from a low of 12.69 to a high of 80.31. The Drug Manufacturers industry median EV-to-OCF is 10.15. Teva Pharmaceutical Industries' value of 30.50 is 200.5% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #799 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Teva Pharmaceutical Industries has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #799 out of 1007 companies for EV-to-OCF. This places Teva Pharmaceutical Industries in the lower half of its industry. The industry median EV-to-OCF is 10.15. Teva Pharmaceutical Industries' value of 30.50 is 200.5% above this benchmark. Historically, Teva Pharmaceutical Industries' own EV-to-OCF has ranged from 12.69 to 80.31 over the past decade. While the company's 10-year median is 28.96 vs. the industry median of 10.15, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current EV-to-OCF of 30.50 is 200.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current EV-to-OCF is 30.50, which is near median its own 10-year median of 28.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (LTS:0LER) is currently considered Significantly Overvalued. The stock's GF Value™ is $20.99, compared to a current price of $37.10 — trading 76.8% above its estimated fair value. The current EV-to-OCF is 30.50, which is near median its 10-year median of 28.96 and 200.5% above the Drug Manufacturers industry median of 10.15. Teva Pharmaceutical Industries' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Teva Pharmaceutical Industries (LTS:0LER), the current EV-to-OCF is 30.50 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (LTS:0LER) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of $37.10 is trading 76.8% above its estimated GF Value™ of $20.99.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for LTS:0LER:
EV-to-OCF: 30.50 (near median its 10-year median of 28.96)
GF Value™: $20.99 vs. price of $37.10 (76.8% above fair value)
Industry Position: 200.5% above the Drug Manufacturers median (#799 of 1007)
No single metric tells the full story. See the LTS:0LER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
39GF Score
Get the complete analysis for LTS:0LER
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LER has been successfully added to your 
